MyFinsight
Home
Blog
About
Proceeds from sale of
common stock and...
$87,500K
(-12.50%↓ Y/Y)
Issuance of common stock
upon exercise of...
$56K
(115.38%↑ Y/Y)
Proceeds from issuance of
common stock under...
$28K
(16.67%↑ Y/Y)
Net cash provided by
financing activities
$81,840K
(-13.26%↓ Y/Y)
Canceled cashflow
$5,744K
Net increase in cash
and cash...
$50,444K
(-56.59%↓ Y/Y)
Canceled cashflow
$31,396K
Payment of pipe
financing related...
$5,654K
(0.52%↑ Y/Y)
Deferred offering costs
paid for financing
$90K
(18.42%↑ Y/Y)
Maturity of short-term
investments
$33,768K
(86.74%↑ Y/Y)
Share-based compensation
expense
$1,520K
(-68.11%↓ Y/Y)
Prepaid expenses and
other current assets
-$755K
(16.67%↑ Y/Y)
Other non-current
assets
-$162K
(-121.15%↓ Y/Y)
Accounts payable and
accrued liabilities
$32K
(101.85%↑ Y/Y)
Depreciation expense
$1K
(-98.63%↓ Y/Y)
Net cash provided by
investing activities
-$16,867K
(-119.46%↓ Y/Y)
Net cash used in
operating activities
-$14,529K
(77.59%↑ Y/Y)
Canceled cashflow
$33,768K
Canceled cashflow
$2,470K
Purchase of short-term
investments
$50,635K
(57.18%↑ Y/Y)
Net (loss) income
-$16,640K
Discount amortization on
short-term investments
$359K
(1809.52%↑ Y/Y)
Back
Back
Cash Flow
Whitehawk Therapeutics, Inc. (WHWK)
Whitehawk Therapeutics, Inc. (WHWK)
source: myfinsight.com